Medivation Stock Hits New 52-Week High (MDVN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Medivation (Nasdaq: MDVN) hit a new 52-week high Friday as it is currently trading at $58.27, above its previous 52-week high of $58.26 with 551,086 shares traded as of 2:41 p.m. ET. Average volume has been 937,400 shares over the past 30 days.

Medivation has a market cap of $4.22 billion and is part of the health care sector and drugs industry. Shares are up 148.4% year to date as of the close of trading on Thursday.

Medivation, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for the treatment of serious diseases in the United States and Europe.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates Medivation as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow, generally higher debt management risk and feeble growth in the company's earnings per share. You can view the full Medivation Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Medivation Founder Takes Helm at Axovant, Shares Spike

Second-Quarter Picks and Pans

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors